Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04388475
Other study ID # OKN-007-IV-RMG-201
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date June 12, 2020
Est. completion date January 31, 2025

Study information

Verified date April 2024
Source Oblato, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase II open-label study investigating the efficacy, safety and pharmacokinetic(PK) properties of OKN-007 combined with temozolomide(TMZ) in patients with recurrent glioblastoma(GBM). All patients will have been previously treated with the standard-of-care treatment which includes surgical resection, radiation and chemotherapy, and in some cases treatment for recurrent disease. Patients with unequivocal recurrence (first or greater) established by MRI and meeting inclusion and exclusion criteria, will be eligible for OKN-007 treatment on this protocol.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 57
Est. completion date January 31, 2025
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Confirmed Glioblastoma based on histopathology or molecular profile analysis (WHO Grade IV), following primary treatment with TMZ and radiotherapy (minimum of 50 Gy) and at least two cycles of maintenance TMZ (5 days of a 28 day cycle) as first-line or second-line treatment with another treatment regimen, excluding bevacizumab. 2. Patients must have medical records available documenting O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status analysis or must have tumor tissue samples available from prior GBM surgery or open biopsy for MGMT status determination. 3. For patients with unresected recurrent tumor, unequivocal radiographic evidence of tumor progression by MRI. These patients must have at least one measurable lesion. 4. Patients with recent resection of recurrent viable tumor are eligible following post-operative MRI perfusion scan with or without measurable lesions. 5. No more than two prior lines of therapy for glioblastoma. Any second-line therapy is acceptable, excluding bevacizumab as second line. 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 7. Full recovery (= grade 1) from the toxic effects. 8. Adequate renal, liver and bone marrow function: - Hemoglobin >9.0 g/dL - Leukocytes >3,000/mcL - Absolute neutrophil count >1,500/mcL - Platelets >100,000/mcL - Total bilirubin = 1.5 × upper limit of normal (ULN) - AST (SGOT) / ALT (SGPT) =2.5 × ULN - Creatinine clearance = 60 mL/min 9. Patients must be =18 years of age Exclusion Criteria: 1. Early discontinuation of TMZ in prior line due to treatment related Adverse events (AEs). 2. Second primary malignancy expected to require treatment within a 6 month period (except adequately treated basal cell carcinoma of the skin). 3. Have received treatment within the last 28 days with a drug that has not received regulatory approval for any indication at the time of study entry. 4. Have received chemotherapeutic agents (including temozolomide) within 28 days or within 5 half-lives for non-cytotoxic agents (whichever is shorter) of study entry 5. Serious concomitant systemic disorders 6. Patients with abnormal sodium, potassium, or creatinine levels = grade 2. 7. Patients with prothrombin time/partial thromboplastin time (PT/PTT) or International normalized ratio (INR) above the ULN. 8. Inability to comply with protocol or study procedures. 9. Patients who have received bevacizumab for recurrent glioblastoma or are planning to initiate treatment with bevacizumab for tumor necrosis. (Past treatment with bevacizumab for tumor necrosis is acceptable). 10. Patients receiving or planning to initiate treatment with the tumor treating fields device (Optune®) (Optune® prior to enrollment is permitted).

Study Design


Intervention

Drug:
OKN-007
Drug: OKN-007 (400 mg OKN-007/mL in a phosphate buffer) Administered via IV infusion, at a dose level of 60 mg/kg, given three times a week for 12 weeks, two times a week for a further 12 weeks and once per week until disease progression or up to two years.
Temozolomide (TMZ)
Administered via oral, at a dose level of 150 mg/m2, once daily on Days 1-5 of each 28 day cycle in Cycle 1. If this dose level is tolerated, then in Cycle 2 (and subsequent cycles), at a dose level of 200 mg/m2, once daily on Days 1-5 of each 28 day cycle.

Locations

Country Name City State
United States University of Alabama at Birmingham Birmingham Alabama
United States Henry Ford Health System Detroit Michigan
United States Swedish Medical Center Englewood Colorado
United States University of Iowa Iowa City Iowa
United States Norton Healthcare Louisville Kentucky
United States The University of Oklahoma Oklahoma City Oklahoma
United States AdventHealth Orlando Orlando Florida
United States St. Joseph's Hospital and Medical Center Phoenix Arizona
United States Lifespan Office of Research Providence Rhode Island
United States Providence Saint John's Health Center - John Wayne Cancer Institute Santa Monica California
United States St. Joseph Hospital of Orange Seattle Washington
United States The University of Toledo Toledo Ohio
United States Wake Forest Baptist Comprehensive Cancer Center Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Oblato, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidents of Adverse Events during the subjects are taking OKN-007 with Temozolomide Evaluate incidents of Adverse Events during the subjects are taking OKN-007 with Temozolomide. Adverse events will be graded according to Common Terminology Criteria for Adverse Events (CTCAE, version 5.0). Through study completion up to 24 months
Primary Number of subjects with decreased neurological function Neurologic function assessed by Neurologic Assessment in Neuro-Oncology (NANO) scale. The NANO Scale evaluates 9 major domains of neurologic function, with each domain being scored on a range from 0 (no deficits) to 2 or 3 (maximum deficits). Change from baseline at Day 1 of each 28 day cycle
Primary Number of subjects with decreased performance Number of participants with decreased performance assessed by Eastern Oncology Cooperative Group (ECOG) scale. Minimum 0 (normal function) and maximum 4 (maximum disability). Change from baseline at Day 1 of each 28 day cycle
Primary Overall Survival (OS) rate Proportion of subjects who are alive after six months of starting treatment. OS is defined as the time from first treatment dose until date of death due to any cause. 6 months
Secondary Radiographic response rate To determine the objective response rate to study therapy using Radiographic Assessment in Neuro-Oncology (RANO) criteria. 24 months
Secondary Progression Free Survival (PFS) rate Proportion of subjects who are alive and progression free after six months of starting treatment. PFS is defined as the time from first treatment dose until objective tumor progression on the RANO criteria or death. 6 months
Secondary Cmax of OKN-007 in blood plasma The sample will be collected at 10 time points during 24 hours after OKN-007 administration. Day 1 and Day 5 in Cycle 1 and 2 (28 Day Cycle)
Secondary AUC of OKN-007 in blood plasma The sample will be collected at 10 time points during 24 hours after OKN-007 administration. Day 1 and Day 5 in Cycle 1 and 2 (28 Day Cycle)
Secondary Tmax of OKN-007 in blood plasma The sample will be collected at 10 time points during 24 hours after OKN-007 administration. Day 1 and Day 5 in Cycle 1 and 2 (28 Day Cycle)
Secondary Cmax of Temozolomide in blood plasma The sample will be collected at 8 time points during 24 hours after Temozolomide administration. Day 1 and Day 5 in Cycle 1 and 2 (28 Day Cycle)
Secondary AUC of Temozolomide in blood plasma The sample will be collected at 8 time points during 24 hours after Temozolomide administration. Day 1 and Day 5 in Cycle 1 and 2 (28 Day Cycle)
Secondary Tmax of Temozolomide in blood plasma The sample will be collected at 8 time points during 24 hours after Temozolomide administration. Day 1 and Day 5 in Cycle 1 and 2 (28 Day Cycle)
See also
  Status Clinical Trial Phase
Recruiting NCT05045027 - Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma Early Phase 1
Recruiting NCT04323046 - Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults Phase 1
Active, not recruiting NCT04284774 - Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Phase 2
Recruiting NCT03598244 - Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors Phase 1
Recruiting NCT05278208 - Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors Phase 1/Phase 2
Active, not recruiting NCT03213665 - Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Active, not recruiting NCT04320888 - Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Phase 2
Recruiting NCT05139056 - Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas Phase 1
Active, not recruiting NCT02208362 - Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma Phase 1
Active, not recruiting NCT02192359 - Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas Phase 1
Unknown status NCT01144988 - Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma Phase 2
Active, not recruiting NCT03210714 - Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Active, not recruiting NCT04195555 - Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Recruiting NCT05540873 - A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma (MAGIC-I) Phase 1
Completed NCT01904123 - STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain Phase 1
Active, not recruiting NCT02658279 - Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype N/A
Withdrawn NCT04521946 - Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer Phase 1
Recruiting NCT04214392 - Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma Phase 1
Recruiting NCT03896568 - MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma Phase 1
Active, not recruiting NCT01672463 - Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients Phase 1